Cargando…
Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas
OBJECTIVE: Ovarian metasteses are often mistaken for primary adenocarcinoma. Studies conducted in recent years have focused on a search for an immunohistochemical marker to aid the differential diagnosis primary and metastatic ovarian carcinoma. Our study objective was to study the usefulness of Wil...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558354/ https://www.ncbi.nlm.nih.gov/pubmed/28913087 http://dx.doi.org/10.4274/tjod.22220 |
_version_ | 1783257376015515648 |
---|---|
author | Şakirahmet Şen, Dilek Gökmen Karasu, Ayşe Filiz Özgün Geçer, Melin Karadayı, Nimet Ablan Yamuç, Elif |
author_facet | Şakirahmet Şen, Dilek Gökmen Karasu, Ayşe Filiz Özgün Geçer, Melin Karadayı, Nimet Ablan Yamuç, Elif |
author_sort | Şakirahmet Şen, Dilek |
collection | PubMed |
description | OBJECTIVE: Ovarian metasteses are often mistaken for primary adenocarcinoma. Studies conducted in recent years have focused on a search for an immunohistochemical marker to aid the differential diagnosis primary and metastatic ovarian carcinoma. Our study objective was to study the usefulness of Wilms tumor 1 (WT 1) antigen in this context. MATERIALS AND METHODS: The study was conducted at the pathology clinic of Lütfi Kırdar Training and Research Hospital. Deparaffinated blocks of 40 epithelial ovarian tumors, 40 colon adenocarcinomas, and 35 cases of omentum metastases were studied. Cytokeratin 7 (CK 7), cytokeratin 20 (CK 20), and WT 1 were applied to all specimens. RESULTS: All ovarian adenocarcinomas were stained with CK 7 (100%). Colorectal adenocarcinomas were stained positive with CK 20 in 87.5% of cases. Primary ovarian adenocarcinomas stained positive with WT 1 in 82.5% of the cases and none of the colorectal adenocarcinomas showed staining with WT 1 (0%). CONCLUSION: WT 1 can be used in conjuction with CK 7 in the differential diagnosis of ovarian carcinomas. |
format | Online Article Text |
id | pubmed-5558354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-55583542017-09-14 Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas Şakirahmet Şen, Dilek Gökmen Karasu, Ayşe Filiz Özgün Geçer, Melin Karadayı, Nimet Ablan Yamuç, Elif Turk J Obstet Gynecol Clinical Investigation OBJECTIVE: Ovarian metasteses are often mistaken for primary adenocarcinoma. Studies conducted in recent years have focused on a search for an immunohistochemical marker to aid the differential diagnosis primary and metastatic ovarian carcinoma. Our study objective was to study the usefulness of Wilms tumor 1 (WT 1) antigen in this context. MATERIALS AND METHODS: The study was conducted at the pathology clinic of Lütfi Kırdar Training and Research Hospital. Deparaffinated blocks of 40 epithelial ovarian tumors, 40 colon adenocarcinomas, and 35 cases of omentum metastases were studied. Cytokeratin 7 (CK 7), cytokeratin 20 (CK 20), and WT 1 were applied to all specimens. RESULTS: All ovarian adenocarcinomas were stained with CK 7 (100%). Colorectal adenocarcinomas were stained positive with CK 20 in 87.5% of cases. Primary ovarian adenocarcinomas stained positive with WT 1 in 82.5% of the cases and none of the colorectal adenocarcinomas showed staining with WT 1 (0%). CONCLUSION: WT 1 can be used in conjuction with CK 7 in the differential diagnosis of ovarian carcinomas. Galenos Publishing 2016-03 2016-03-10 /pmc/articles/PMC5558354/ /pubmed/28913087 http://dx.doi.org/10.4274/tjod.22220 Text en © Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Investigation Şakirahmet Şen, Dilek Gökmen Karasu, Ayşe Filiz Özgün Geçer, Melin Karadayı, Nimet Ablan Yamuç, Elif Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title | Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title_full | Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title_fullStr | Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title_full_unstemmed | Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title_short | Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
title_sort | utilization of wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558354/ https://www.ncbi.nlm.nih.gov/pubmed/28913087 http://dx.doi.org/10.4274/tjod.22220 |
work_keys_str_mv | AT sakirahmetsendilek utilizationofwilmstumor1antigeninapanelfordifferentialdiagnosisofovariancarcinomas AT gokmenkarasuaysefiliz utilizationofwilmstumor1antigeninapanelfordifferentialdiagnosisofovariancarcinomas AT ozgungecermelin utilizationofwilmstumor1antigeninapanelfordifferentialdiagnosisofovariancarcinomas AT karadayınimet utilizationofwilmstumor1antigeninapanelfordifferentialdiagnosisofovariancarcinomas AT ablanyamucelif utilizationofwilmstumor1antigeninapanelfordifferentialdiagnosisofovariancarcinomas |